Effects of two different dexamethasone dosing regimens on ventilator-free days and long-term mortality in COVID-19 patients with moderate-to-severe ARDS: the REMED randomized clinical trial

Effects of two different dexamethasone dosing regimens on ventilator-free days and long-term mortality in COVID-19 patients with moderate-to-severe ARDS: the REMED randomized clinical trial

Abstract Background Dexamethasone 6 mg in patients with severe COVID-19 has been shown to decrease mortality and morbidity. The effects of higher doses of corticosteroid, that would further increase anti-inflammatory effects, are uncertain. The objective of our study was to assess the effect of 20 m...

Full description

Bibliographic Details
Main Authors: Jan Maláska, Jan Stašek, Jan Máca, Martin Kutěj, František Duška, Petr Kafka, Olga Klementová, Lenka Doubravská, Jan Hruda, Marek Fencl, Tomáš Gabrhelík, Libor Číž, Jan Zatloukal, Jiří Pouska, Pavel Novotný, Martin Balík, Regina Demlová, Jana Kubátová, Jana Vinklerová, Karolína Grodová, Radka Štěpánová, Adam Svobodník, Milan Kratochvíl, Jozef Klučka, Petr Štourač, Mervyn Singer, the REMED Study Group
Format: Article
Language:English
Published: BMC 2024-12-01
Series:European Journal of Medical Research
Subjects:
COVID-19
ARDS
Dexamethasone
Randomized clinical trial
Ventilator-free days
Long-term outcomes
Online Access:https://doi.org/10.1186/s40001-024-02215-6

Internet

https://doi.org/10.1186/s40001-024-02215-6

Similar Items